3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
7
Lung Neoplasms
6
Colorectal Neoplasms
5
Prostatic Neoplasms
3
Smoking Cessation
2
Neoplasm Metastasis
2
Lymphoma
2
Colonic Neoplasms
2
Breast Neoplasms
2
Uveal Melanoma
1
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Retroviridae Infections
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm, Residual
1
Multiple Myeloma
1
Motor Activity
1
Leukemia
1
Inflammation
1
Glioblastoma
1
Esophageal Neoplasms
1
Dyspnea
1
Disease
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Carcinoma, Transitional Cell
1
Interventions
Paclitaxel
69
Bevacizumab
62
Carboplatin
53
pembrolizumab
46
olaparib
32
Specimen Handling
27
Gemcitabine
27
Cyclophosphamide
26
Magnetic Resonance Spectroscopy
24
liposomal doxorubicin
22
Cisplatin
21
niraparib
20
Taxes
18
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
12
Fulvestrant
12
Disulfides
12
Oxaliplatin
10
mirvetuximab soravtansine
9
durvalumab
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
Blood Specimen Collection
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Hematologic Tests
×
1 year
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled